ClinicalTrials.gg
RecruitingNCT07351058Enith2Updated Nov 9, 2026

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

A Phase 3 interventional study of Placebo and Enicepatide in Obesity or Overweight and Type 2 Diabetes Mellitus, sponsored by Hoffmann-La Roche. Recruiting at 222 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 9, 2026First sites in Romania and India18 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.

Planned enrollment
5th of 21
1,600 · median 300
Started
2026
with 7 others
Phase 3
8 of 21
7 open now
Primary completion
2028-08
later than 7 of 11 live
Registered
13th of 21
by date

Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 5th largest by planned enrollment, is one of 8 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 7 of the 11 other live ones, and was the 13th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Obesity by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).

03

Conditions studied

  • Obesity or Overweight
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)
  • Diagnosis of type 2 diabetes mellitus (T2DM) according to WHO classification or other locally applicable standards with ≥6.5% to ≤10% determined by laboratory test at screening, and on stable oral therapy for at least 3 months prior to screening (if applicable). T2DM may be treated with diet/exercise alone or any oral anti-hyperglycemic medication (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1 RA-based therapy.
  • (BMI) ≥27.0 kg/m\^2
  • History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus (T1DM) or any lifetime history of ketoacidosis or history of hyperosmolar state/coma within 12 months prior to screening
  • Have had 1 or more episodes of severe hypoglycemia and/or has hypoglycemia unawareness within the 6 months prior to screening
  • At least 2 confirmed fasting blood glucose values >270 mg/dL (15.0 mmol/L) (on 2 non-consecutive days) during screening
  • Self-reported change in body weight >5 kg within 3 months prior to screening
  • Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome)
  • Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed.
  • Known gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction)
  • Poorly controlled hypertension at screening
  • Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/; Unstable angina; Hospitalization due to congestive heart failure
  • Treatment with any approved or GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1/GIP receptor dual agonist, GLP-1/GIP/Gluc receptor triple agonist) within 6 months prior to randomization
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,600 participants (estimated)

Study arms

  • Placebo comparator
    Arm 1: Placebo

    Combination Product: Placebo

  • Experimental
    Arm 2: Enicepatide Dosing Regimen 1

    Combination Product: Enicepatide

  • Experimental
    Arm 3: Enicepatide Dosing Regimen 2

    Combination Product: Enicepatide

  • Experimental
    Arm 4: Enicepatide Dosing Regimen 3

    Combination Product: Enicepatide

Interventions

  • Combination productPlacebo

    Placebo will be volume-matched and administered once weekly using an integrated drug-device combination product.

  • Combination productEnicepatide

    Enicepatide will be administered once weekly at the randomized dosing regimen using an integrated drug-device combination product.

    Also known as: RO7795068, CT-388, RG6640

06

What researchers measure

Primary outcomes

  1. Percent (%) Change from Baseline in Body Weight at Week 72

    Time frame: Baseline through Week 72

Secondary outcomes

  1. Percentage of Participants Achieving ≥5% Body Weight Loss from Baseline at Week 72

    Time frame: Baseline and Week 72

  2. Percentage of Participants Achieving ≥10% Body Weight Loss from Baseline at Week 72

    Time frame: Baseline and Week 72

  3. Percentage of Participants Achieving ≥15% Body Weight Loss from Baseline at Week 72

    Time frame: Baseline and Week 72

  4. Change from Baseline in Body Weight (kg) at Week 72

    Time frame: Baseline through Week 72

  5. Change from Baseline in Hemoglobin A1c (HbA1c) at Week 72

    Time frame: Baseline through Week 72

  6. Percentage of Participants Achieving HbA1c of ≤6.5% at Week 72

    Time frame: Week 72

  7. Percentage of Participants Achieving HbA1c of <7% at Week 72

    Time frame: Week 72

  8. Change from Baseline in Waist Circumference (cm) at Week 72

    Time frame: Baseline through Week 72

  9. Change from Baseline in Fasting Glucose at Week 72

    Time frame: Baseline through Week 72

  10. Change from Baseline in Fasting Insulin at Week 72

    Time frame: Baseline through Week 72

  11. Change from Baseline in Low-Density Lipoprotein (LDL) Cholesterol at Week 72

    Time frame: Baseline through Week 72

  12. Change from Baseline in High-Density Lipoprotein (HDL) Cholesterol at Week 72

    Time frame: Baseline through Week 72

  13. Change from Baseline in Triglyceride at Week 72

    Time frame: Baseline through Week 72

  14. Change from Baseline in Systolic Blood Pressure at Week 72

    Time frame: Baseline through Week 72

  15. Change from Baseline in the Physical Functioning Domain Score of the Short Form (36) Health Survey Version 2 (SF-36v2) Acute Form at Week 72

    Time frame: Baseline through Week 72

  16. Change from Baseline in Physical Functioning Composite Score of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQoL-Lite-CT) Questionnaire at Week 72

    Time frame: Baseline through Week 72

  17. Change from Baseline in Waist-to-Hip Ratio at Week 72

    Time frame: Baseline through Week 72

  18. Change from Baseline in Waist-to-Height Ratio at Week 72

    Time frame: Baseline through Week 72

  19. Change from Baseline in Subscale Scores of the Control of Eating Questionnaire (CoEQ) at Week 72

    Time frame: Baseline through Week 72

  20. Change from Baseline in Symptoms and Impact of Urinary Incontinence as Assessed by the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) at Week 72

    Time frame: Baseline through Week 72

  21. Percentage of Participants Experiencing No Change, Improvement, or Worsening on the Patient Global Impression of Change (PGI-C) Urinary Incontinence Questionnaire at Week 72

    Time frame: Baseline and Week 72

  22. Percentage of Participants Experiencing No Change, Improvement, or Worsening on the Patient Global Impression of Severity (PGI-S) Urinary Incontinence Questionnaire at Week 72

    Time frame: Baseline and Week 72

  23. Percentage of Participants Experiencing No Change, Improvement, or Worsening on the PGI-C Physical Functioning Questionnaire at Week 72

    Time frame: Baseline and Week 72

  24. Percentage of Participants Experiencing No Change, Improvement, or Worsening on the PGI-S Physical Functioning Questionnaire at Week 72

    Time frame: Baseline and Week 72

  25. Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the SF-36v2 Acute Form Domain Scores and Component Summary Scores at Week 72

    Time frame: Baseline through Week 72

  26. Change from Baseline in HRQoL as Assessed by the IWQoL-Lite-CT Domain Scores and Total Score at Week 72

    Time frame: Baseline through Week 72

  27. Change from Baseline in Non-HDL Cholesterol at Week 72

    Time frame: Baseline through Week 72

  28. Change from Baseline in VLDL Cholesterol at Week 72

    Time frame: Baseline through Week 72

  29. Change from Baseline in Total Cholesterol at Week 72

    Time frame: Baseline through Week 72

  30. Change from Baseline in Free Fatty Acids at Week 72

    Time frame: Baseline through Week 72

  31. Change from Baseline in Diastolic Blood Pressure at Week 72

    Time frame: Baseline through Week 72

  32. Change from Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 72

    Time frame: Baseline through Week 72

  33. Change from Baseline in Urinary Albumin/Creatinine Ratio at Week 72

    Time frame: Baseline through Week 72

  34. Change from Baseline in Body Mass Index (BMI) at Week 72

    Time frame: Baseline through Week 72

  35. Percent (%) Change from Baseline in Body Weight by Obesity Class at Week 72

    Time frame: Baseline through Week 72

  36. Time to Achieve ≥5%, ≥10%, or ≥15% Body Weight Loss from Baseline Through Week 72

    Time frame: From Baseline through Week 72

  37. Percentage of Participants Achieving HbA1c of <5.7% at Week 72

    Time frame: Week 72

  38. Incidence and Severity of Adverse Events, with Severity Determined According to Mild/Moderate/Severe Criteria

    Time frame: Baseline through Week 72

  39. Change from Baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS) Score Through Week 72

    Time frame: Baseline through Week 72

  40. Change from Baseline in the Patient Health Questionnaire-9 (PHQ-9) Score Through Week 72

    Time frame: Baseline through Week 72

07

Study locations

222 of 222 sites recruiting

Showing the first 100 of 222 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2028, 28 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 28 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 20, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Aug 7, 2028
CompletionEst.
Aug 7, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added — first sites in Romania and India
Show 18 added (8 India, 5 Romania, 3 United States, 1 China, 1 Czechia)
  • University of California Irvine · Irvine, United States
  • Atlanta Veterans Affairs Medical Center · Decatur, United States
  • Central Illinois Diabetes and Clinical Research · Springfield, United States
  • The First Affiliated Hospital of Xi'an Medical University · Xi'an, China
  • Institut klinické a experimentální medicíny (IKEM);centrum diabetologie · Prague, Czechia
  • Spitalul Clinic Judetean de Urgenta 'Pius Brinzeu' Timisoara · Timișoara, Romania
  • Marengo CIMS Hospital · Ahmedabad, India
  • Jothydev's Diabetes Research Centre · Trivandrum, India
  • TOTALL Diabetes Hormone Institute · Indore, India
  • Topiwala National Medical College (TNMC) And Bai Yamunabai Laxman (BYL) Nair Charitable Hospital · Mumbai, India
  • Deenanath Mangeshkar Hospital & Research Centre · Pune, India
  • Chellaram Diabetes Institute;Diabetes and Endocrinology · Pune, India
  • Madras Diabetes Research Foundation · Chennai, India
  • Osmania General Hospital · Hyderabad, India
  • Spitalul Clinic Judetean de Urgenta Cluj Napoca · Cluj-Napoca, Romania
  • SC Diabmed Dr Popescu Alexandrina SRL · Ploieşti, Romania
  • Top Diabet SRL · Craiova, Romania
  • SC Consult Med Srl · Iași, Romania
across 2 updates, Oct 13, 2026 – Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    12 sites added — first site in India
    Show 12 added (8 India, 4 Romania)
    • Marengo CIMS Hospital · Ahmedabad, India
    • Jothydev's Diabetes Research Centre · Trivandrum, India
    • TOTALL Diabetes Hormone Institute · Indore, India
    • Topiwala National Medical College (TNMC) And Bai Yamunabai Laxman (BYL) Nair Charitable Hospital · Mumbai, India
    • Deenanath Mangeshkar Hospital & Research Centre · Pune, India
    • Chellaram Diabetes Institute;Diabetes and Endocrinology · Pune, India
    • Madras Diabetes Research Foundation · Chennai, India
    • Osmania General Hospital · Hyderabad, India
    • Spitalul Clinic Judetean de Urgenta Cluj Napoca · Cluj-Napoca, Romania
    • SC Diabmed Dr Popescu Alexandrina SRL · Ploieşti, Romania
    • Top Diabet SRL · Craiova, Romania
    • SC Consult Med Srl · Iași, Romania
    + 1 other change: verification date
  2. Oct 13, 2026
    6 sites added — first site in Romania
    Show 6 added (3 United States, 1 China, 1 Czechia, 1 Romania)
    • University of California Irvine · Irvine, United States
    • Atlanta Veterans Affairs Medical Center · Decatur, United States
    • Central Illinois Diabetes and Clinical Research · Springfield, United States
    • The First Affiliated Hospital of Xi'an Medical University · Xi'an, China
    • Institut klinické a experimentální medicíny (IKEM);centrum diabetologie · Prague, Czechia
    • Spitalul Clinic Judetean de Urgenta 'Pius Brinzeu' Timisoara · Timișoara, Romania
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07351058
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Mar 23, 2026
Primary completion
Aug 7, 2028 (estimated)
Completion
Aug 7, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Reference Study ID Number: WC45726 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enicepatide

Start the discussion